Drugs / INCB057643
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06941077 | May → Jun 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT04279847 | Feb 2021 → Apr 2027 expected | essential thrombocythemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm, myelofibrosis +1 | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02959437 | Feb 2017 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02711137 | May 2016 → Feb 2019 | cancer | Incyte Corporation | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | Incyte Corporation | Results Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 incyte.com ↗
Bromodomain and Extra-Terminal (BET) Protein Inhibitor, INCB057643, Improves Bone Marrow Function and Shifts Megakaryopoiesis to Erythropoiesis in Patients with Myeloproliferative Neoplasms (MPNs) |
| 2025-04-25 | Incyte Corporation | Results Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 incyte.com ↗
INCB057643, a Bromodomain and Extra-Terminal (BET) Protein Inhibitor, Improved Bone Marrow Function and Shifted Megakaryopoiesis to Erythropoiesis in Patients with Myeloproliferative Neoplasms (MPNs) |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-03 | Incyte Corporation | Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025 incyte.com ↗ |
| 2025-04-25 | Incyte Corporation | Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025 incyte.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB057643 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04279847 ↗ |
| Action | Inhibit | “BET inhibitors INCB054329 (study INCB 54329-101; NCT02431260) and INCB057643 (study INCB 57643-101; NCT02711137)” PMID 31527168 ↗ Sep 2019 |
| Modality | Small molecule | — CHEMBL4594412 ↗ |
| Route | Oral | “received oral INCB054329 (monotherapy) or INCB057643 (monotherapy or in combination with standard-of-care)” PMID 31527168 ↗ Sep 2019 |